A Tale of Two Legacies: Scientific Breakthrough and Legal Scandal at Chinook
Published on 09/19/2025 at 12:36 | Redaktion boerse-global.deThe 2023 acquisition of biopharmaceutical firm Chinook Therapeutics by Swiss giant Novartis has culminated in a stark narrative of contrast. Two years later, the deal exemplifies both the pinnacle of medical achievement and a profound breach of legal and ethical standards.
The scientific promise that drove Novartis to complete its $3.2 billion purchase of Chinook in August 2023 has begun to bear fruit. In a significant development for patients, the U.S. Food and Drug Administration (FDA) granted accelerated approval in April 2025 for the drug Vanrafia. Previously known as atrasentan, this once-daily tablet was a crown jewel in Chinook’s pipeline. Clinical data demonstrated its efficacy in reducing proteinuria?a key marker of kidney damage?by 36.1% in individuals suffering from IgA nephropathy, a... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
